SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors
- 12 May 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 156 (5) , 853-865
Abstract
Objectives: To evaluate SATB2 expression and prognostic implications in a large cohort of thoracic neuroendocrine tumors. Methods: Surgical pathology files (1995-2017) and an institutional thymic epithelial tumor database (2010-2020) were searched for resected neuroendocrine tumors. Cases were stained with SATB2 (clone EP281). Percent SATB2-positive tumor cells and expression intensity were scored. Results: In the lung, SATB2 was expressed in 5% or more of tumor cells in 29 (74.4%) of 39 small cell carcinomas and 9 (22.5%) of 40 atypical and 26 (40.6%) of 64 typical carcinoid tumors. SATB2 percent tumor cell expression and intensity were higher in small cell carcinomas than in carcinoid tumors (both P < .001, respectively). After adjusting for tumor subtype, SATB2 expression did not correlate with outcome. In the thymus, four (100%) of four atypical carcinoid tumors and one large cell neuroendocrine carcinoma but no small cell carcinoma (n = 2) expressed SATB2 in 5% or more of tumor cells. Conclusions: SATB2 (clone EP281) is expressed in a large subset of pulmonary and thymic neuroendocrine tumors and therefore does not appear to be a useful marker to identify the origin of neuroendocrine tumors. Validation studies are needed, specifically including thymic neuroendocrine tumors, as the expression pattern might be different in those tumors.Keywords
This publication has 43 references indexed in Scilit:
- Decreased Expression of SATB2: A Novel Independent Prognostic Marker of Worse Outcome in Laryngeal Carcinoma PatientsPLOS ONE, 2012
- A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancerBritish Journal of Cancer, 2012
- Phenotyping of pulmonary carcinoids and a Ki-67-based grading approachVirchows Archiv, 2012
- SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal CarcinomasAmerican Journal of Surgical Pathology, 2011
- Down‐regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancerThe Journal of Pathology, 2009
- Immunohistochemical Staining for CDX-2, PDX-1, NESP-55, and TTF-1 Can Help Distinguish Gastrointestinal Carcinoid Tumors From Pancreatic Endocrine and Pulmonary Carcinoid TumorsAmerican Journal of Surgical Pathology, 2009
- Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown OriginApplied Immunohistochemistry & Molecular Morphology, 2007
- Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 casesBMC Cancer, 2007
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Thyroid Transcription Factor-1 Is Expressed in Extrapulmonary Small Cell Carcinomas but Not in Other Extrapulmonary Neuroendocrine TumorsLaboratory Investigation, 2000